Evidence map›Paper›PMID 41504001›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2026

Aggressive Glioblastoma Cells Enhance the Migratory Persistence and Velocity of Less Aggressive Cells to Promote Tumor Dissemination.

Fatima-Ezzahra Ait Mohand, Shaked Yemini, Irina Gorobetz-Cojocari, Ariel M Rubinstein, Assaf Zemel, Nataly Kravchenko-Balasha

Abstract read
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fatima-Ezzahra Ait MohandThe Institute of Biomedical and Oral Research, Hebrew University of Jerusalem, Jerusalem, Israel.
Shaked YeminiThe Institute of Biomedical and Oral Research, Hebrew University of Jerusalem, Jerusalem, Israel.
Irina Gorobetz-CojocariThe Institute of Biomedical and Oral Research, Hebrew University of Jerusalem, Jerusalem, Israel.
Ariel M RubinsteinThe Institute of Biomedical and Oral Research, Hebrew University of Jerusalem, Jerusalem, Israel.
Assaf ZemelThe Institute of Biomedical and Oral Research, Hebrew University of Jerusalem, Jerusalem, Israel.
Nataly Kravchenko-BalashaThe Institute of Biomedical and Oral Research, Hebrew University of Jerusalem, Jerusalem, Israel.ORCID https://orcid.org/0000-0001-6943-7479

Funding

Hebrew University of Jerusalem
6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) is a highly lethal brain cancer driven by aggressive invasion. Epidermal growth factor receptor (EGFR) is frequently amplified in GBM, with the EGFRvIII mutant enhancing the infiltrative features of EGFRwt-overexpressing cells. Previously, we identified Src as a key cell-cell communication mediator between EGFRvIII and EGFRwt cells. However, a quantitative biophysical characterization of how EGFRvIII induces this increased infiltration, specifically detailing altered movement parameters and the underlying mechanisms, remains lacking. Using bulk cell culture and 2-cell microfluidic chips, we quantitatively analyzed the motility of EGFRwt-overexpressing and EGFRvIII-expressing GBM cells. We observed that EGFRvIII cells exhibit higher migration velocity and persistence compared to EGFRwt cells, with a highly persistent subpopulation contributing significantly to these differences. Notably, the co-culture of EGFRvIII cells enhanced the velocity and migration persistence of EGFRwt-overexpressing cells, leading to increased spreading. Our findings revealed that Src-mediated cell-cell communication from EGFRvIII-expressing to EGFRwt-overexpressing cells promotes aggressive GBM spreading by increasing both their velocity and migration persistence at the micro-environmental level. Inhibiting the Src pathway with dasatinib reversed this pro-migratory effect, markedly reducing their migration persistence. These insights refine our understanding of GBM infiltration and highlight Src inhibition as a promising strategy in EGFRvIII-positive tumors.

Indexed as

Brain NeoplasmsCell MovementGlioblastomaAnimalsCell CommunicationCell Line, TumorDasatinibErbB ReceptorsHumanssrc-Family KinasesDasatinibepidermal growth factor receptor VIIIErbB Receptorssrc-Family Kinases

Identifiers

PMID41504001
PMCPMC12921552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.